150 related articles for article (PubMed ID: 22254256)
1. Simplification of an erythropoiesis model for design of anemia management protocols in end stage renal disease.
Nichols B; Shrestha RP; Horowitz J; Hollot CV; Germain MJ; Gaweda AE; Chait Y
Annu Int Conf IEEE Eng Med Biol Soc; 2011; 2011():83-6. PubMed ID: 22254256
[TBL] [Abstract][Full Text] [Related]
2. Control-relevant erythropoiesis modeling in end-stage renal disease.
Chait Y; Horowitz J; Nichols B; Shrestha RP; Hollot CV; Germain MJ
IEEE Trans Biomed Eng; 2014 Mar; 61(3):658-64. PubMed ID: 24235247
[TBL] [Abstract][Full Text] [Related]
3. Optimal EPO dosing in hemodialysis patients using a non-linear model predictive control approach.
Rogg S; Fuertinger DH; Volkwein S; Kappel F; Kotanko P
J Math Biol; 2019 Dec; 79(6-7):2281-2313. PubMed ID: 31630225
[TBL] [Abstract][Full Text] [Related]
4. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of anemia in chronic renal failure by a long-activing activator of erythropoiesis].
Ureña P
Presse Med; 2002 Mar; 31(11):505-14. PubMed ID: 11963378
[TBL] [Abstract][Full Text] [Related]
6. Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure.
Ahluwalia N; Skikne BS; Savin V; Chonko A
Am J Kidney Dis; 1997 Oct; 30(4):532-41. PubMed ID: 9328369
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin converting enzyme inhibitors impair recombinant human erythropoietin induced erythropoiesis in patients with chronic renal failure.
Qureshi IZ; Abid K; Ambreen F; Qureshi AL
Saudi Med J; 2007 Feb; 28(2):193-6. PubMed ID: 17268695
[TBL] [Abstract][Full Text] [Related]
8. Darbepoetin alfa: a novel erythropoiesis-stimulating protein.
Cases A
Drugs Today (Barc); 2003 Jul; 39(7):477-95. PubMed ID: 12973399
[TBL] [Abstract][Full Text] [Related]
9. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency.
Locatelli F; Olivares J; Walker R; Wilkie M; Jenkins B; Dewey C; Gray SJ;
Kidney Int; 2001 Aug; 60(2):741-7. PubMed ID: 11473657
[TBL] [Abstract][Full Text] [Related]
10. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Pisoni RL; Bragg-Gresham JL; Young EW; Akizawa T; Asano Y; Locatelli F; Bommer J; Cruz JM; Kerr PG; Mendelssohn DC; Held PJ; Port FK
Am J Kidney Dis; 2004 Jul; 44(1):94-111. PubMed ID: 15211443
[TBL] [Abstract][Full Text] [Related]
11. Variations in erythropoiesis and serum ferritin during erythropoietin therapy for anaemia of end-stage renal disease.
Barosi G; Merlo C; Palestra P; Liberato NL; Guarnone R; Di Dio F; Piazza V; Salvadeo A
Acta Haematol; 1993; 90(1):13-8. PubMed ID: 8237268
[TBL] [Abstract][Full Text] [Related]
12. Anemia of chronic kidney disease: when normalcy becomes undesirable.
Demirjian SG; Nurko S
Cleve Clin J Med; 2008 May; 75(5):353-6. PubMed ID: 18556877
[TBL] [Abstract][Full Text] [Related]
13. Protocolized anemia management with erythropoietin in hemodialysis patients: a randomized controlled trial.
Brimble KS; Rabbat CG; McKenna P; Lambert K; Carlisle EJ
J Am Soc Nephrol; 2003 Oct; 14(10):2654-61. PubMed ID: 14514745
[TBL] [Abstract][Full Text] [Related]
14. Model predictive control of erythropoietin administration in the anemia of ESRD.
Gaweda AE; Jacobs AA; Aronoff GR; Brier ME
Am J Kidney Dis; 2008 Jan; 51(1):71-9. PubMed ID: 18155535
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin requirements increase following hospitalization in end-stage renal disease patients.
Yaqub MS; Leiser J; Molitoris BA
Am J Nephrol; 2001; 21(5):390-6. PubMed ID: 11684801
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of indicators of erythropoiesis stimulated by recombinant human erythropoietin in renal anemia.
Schmidt G; Stamminger G; Daniel A; Gross J; Syllm-Rapoport I; Lun A; Zoellner K
Biomed Biochim Acta; 1990; 49(2-3):S275-9. PubMed ID: 2386517
[TBL] [Abstract][Full Text] [Related]
17. Using clinical information in goal-oriented learning.
Gaweda AE; Muezzinoglu MK; Aronoff GR; Jacobs AA; Zurada JM; Brier ME
IEEE Eng Med Biol Mag; 2007; 26(2):27-36. PubMed ID: 17441606
[TBL] [Abstract][Full Text] [Related]
18. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
19. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
Kessler M; Hannedouche T; Fitte H; Cayotte JL; Urena P; Réglier JC;
Nephrol Ther; 2006 Sep; 2(4):191-9. PubMed ID: 16966064
[TBL] [Abstract][Full Text] [Related]
20. Drug delivery optimization through Bayesian networks: an application to erythropoietin therapy in uremic anemia.
Bellazzi R
Comput Biomed Res; 1993 Jun; 26(3):274-93. PubMed ID: 8325006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
